

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO

Application Number

09/925,673

Filing Date

August 9, 2001

First Named Inventor

Masakatsu KANEKO et al

Group Art Unit

1623

Examiner Name

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet

1

of

3

Attorney Docket Number

01376CIP/HG

U.S. PATENT DOCUMENTS

Exam. Inits ¹	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
Ho		3,687,808		Merigan Jr., et al	08-29-1972	
Ho		4,689,320		Kaji	08-25-1987	
Ho		4,806,463		Goodchild et al	02-21-1989	
Ho		5,514,577		Draper et al	05-07-1996	
Ho		5,661,134		Cook et al	08-26-1997	
Ho		5,004,810		Draper	04-02-1991	
Ho		5,166,195		Ecker	11-24-1992	
Ho		5,194,428		Agrawi et al	03-16-1993	
Ho		5,242,906		Pagano et al	09-07-1993	
Ho		5,248,670		Draper et al	09-28-1993	
Ho		5,442,049		Anderson et al	08-15-1995	

FOREIGN PATENT DOCUMENTS

Exam. Inits ¹	Cite No ¹	Offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
Ho		WO	94/08003	A	ISIS PHARMA., INC.	04-14-1994		
Ho		WO	96/31557	A	JACOBSEN et al	10-10-1996		
Ho		WO	98/39352 (abstract only)	A		09-11-1998		
Ho		WO	99/14226	A	EXIQON A/S	03-25-1999		

Examiner
Signature*David Chen*Date
Considered

5-29-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.DATE MAILED: October 31, 2001RECEIVED
DEC 4 2001
TECH CENTER 1600/2900

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO

Application Number

09/925,673

Filing Date

August 9, 2001


First Named Inventor

Masakatsu KANEKO et

Group Art Unit

1623

Examiner Name

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet

2

of

3

Attorney Docket Number

01376CIP/HG

U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
<i>Ho</i>		5,457,189		Crooke et al	10-10-1995	
		5,514,788		Bennett et al	05-07-1996	
		5,523,389		Ecker et al	06-04-1996	
		5,580,767		Cowser et al	¹² 10 -03-1996	
		5,582,972		Lima et al	¹² 10 -10-1996	
		5,582,986		Monia et al	12-10-1996	
		5,591,600		Ecker	01-07-1997	
		5,591,623		Bennett et al	01-07-1997	
		5,591,720		Anderson et al	01-07-1997	
		5,607,923		Cook et al	03-04-1997	
		5,620,963		Cook et al	04-15-1997	
		5,658,891		Draper et al	08-19-1997	
		5,681,747		Boggs et al	10-28-1997	
<i>Ho</i>		5,681,944		Crooke et al	10-28-1997	

FOREIGN PATENT DOCUMENTS

Exam. Inits*	Cite No ¹	Offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
Examiner Signature	<i>Howard Davis</i>				Date Considered	<i>5-29-03</i>		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE MAILED: October 31, 2001

RECEIVED

DEC 4 2001
TECH CENTER 1600/2900

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO

Application Number

09/925,673

Filing Date

August 9, 2001

First Named Inventor


Masakatsu KANEKO et

Group Art Unit

1623

Examiner Name

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT



RECEIVED
DEC 04 2001
TECH CENTER 7600/2900

Sheet

3

of

3

Attorney Docket Number

01376CIP/HG

U.S. PATENT DOCUMENTS

Exam. Inits [*]	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
Ho ↓ Ho		5,691,461		Ecker et al	11-25-1997	
		5,877,309		McKay et al	03-02-1999	
		5,955,443		Bennett et al	09-21-1999	
		5,985,558		Dean et al	11-16-1999	
		6,111,094		Bennett et al	08-29-2000	
		6,127,533		Cook et al	10-03-2000	

FOREIGN PATENT DOCUMENTS

Exam Inits [*]	Cite No ¹	Offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶

Examiner
Signature

[Handwritten Signature]

Date
Considered

5-29-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE MAILED: **October 31, 2001**

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/925,673
				Filing Date	August 9, 2001
				First Named Inventor	Masakatsu KANEKO
				Group Art Unit	1623
				Examiner Name	
Sheet	1	of	6	Attorney Docket Number	01376CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Ho		<p>GRIFFITHS et al, "Keratinocyte Intercellular Adhesion Molecule-1 (ICAM-1) Expression Precedes Dermal T Lymphomatic Infiltration...", <u>American Journal of Path.</u>, Dec. 1989, Vol. 135, No. 6, pp. 1045-1053.</p> <p>THUONG et al, "Sequence-Specific Recognition and Modification of Double-Helical DNA by Oligonucleotides", <u>Angew. Chem. Int. Ed. Engl.</u>, 1993, <u>32</u>, pp. 666-690.</p> <p>MANOHARAN et al, "Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides", <u>Ann. N.Y. Acad. of Sciences</u>, 1992, <u>660</u>, PP. 306-309.</p> <p>STETLER-STEVENSON et al, "TUMOR CELL INTERACTIONS WITH THE EXTRACELLULAR MATRIX DURING INVASION AND METASTASIS", <u>Annu. Rev. Cell Biol.</u>, 1993, <u>9</u>, pp. 541-573.</p> <p>COOK, " Medicinal chemistry of antisense oligonucleotides - future opportunities", <u>Anti-Cancer Drug Design</u>, 1991, <u>6</u>, pp. 585-607.</p> <p>SANGHVI, "HETEROCYCLIC BASE MODIFICATIONS IN NUCLEIC ACIDS AND THEIR APPLICATIONS IN ANTISENSE OLIGONUCLEOTIDES", <u>Antisense Research and Applications</u>, 1993, Chapter 15, pp. 273-288.</p> <p>SHIOHARA et al, "Fixed Drug Eruption", <u>Arch Dermatol.</u>, Oct. 1989, Vol. 125, pp. 1371-1376.</p> <p>MISHRA et al, "Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery", <u>Biochim. Biophys. Acta</u>, 1995, <u>1264</u>, pp. 229-237.</p> <p>SVINARCHUK et al, Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups", <u>Biochimie</u>, 1993, <u>75</u>, pp. 49-54.</p>	
Examiner Signature		Date Considered	7-6-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: **November 7, 2001**



Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/925,673
				Filing Date	August 9, 2001
				First Named Inventor	Masakatsu KANEKO et al
				Group Art Unit	1623
				Examiner Name	
Sheet	2	of	6	Attorney Docket Number	01376CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
HO		MANOHARAN et al, "INTRODUCTION OF A LIPOPHILIC THIOETHER TETHER IN THE MINOR GROOVE OF NUCLEIC ACIDS FOR ANTISENSE APPLICATIONS", <u>Bioorg. Med. Chem. Lett.</u> , 1993, Vol. 3, No. 12, pp. 2765-2770.	
HO		MANOHARAN et al, "CHOLIC ACID-OLIGONUCLEOTIDE CONJUGATES FOR ANTISENSE APPLICATIONS", <u>Bioorg. Med. Chem. Lett.</u> , 1994, Vol. 4, No. 8, pp. 1053-1060.	
HO		LISBY et al, "Intercellular adhesion molecule-I (ICAM-I) expression correlated to inflammation", <u>Br. J. of Dermatol.</u> , 1989, <u>120</u> , 479-484.	
HO		MAHER III, "Prospects for the Therapeutic Use of Antigene Oligonucleotides", <u>Cancer Investigation</u> , 1996, <u>14(1)</u> , pp. 66-82.	
HO		BIRKEDAL-HANSEN, "Proteolytic remodeling of extracellular matrix", <u>Current Op. Biol.</u> , 1995, <u>7</u> , pp. 728-735.	
HO		LeROITH et al, "Molecular and Cellular Aspects of the Insulin-Like Growth Factor I Receptor", <u>Endocr. Rev.</u> , 1995, Vol. 16, No. 2, pp. 143-163.	
HO		KABANOV et al, "A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent...", <u>FEBS Lett.</u> , Jan. 1990, Vol. 259, No. 2, pp. 327-330.	
HO		MARTIN, "A New Access to 2'-O Alkylated Ribonucleosides and Properties of 2'-O Alkylated Oligoribonucleotides", <u>Helv. Chim. Acta</u>, 1995, Vol. 78, pp. 486-504.	
HO		DeLISSER et al, "Molecular and functional aspects of PECAM-1/CD31" <u>Immunol. Today</u> , 1994, Vol. 15, No. 10, pp. 490-495.	
HO		HIMELSTEIN et al, "Metalloproteinases in Tumor Progression: The Contribution of MMP-9", <u>Invasion Metastasis</u> , 1994-95, <u>14</u> , pp. 246-258.	
Examiner Signature			Date Considered 7-6-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: **November 7, 2001**

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/925,673
				Filing Date	August 9, 2001
				First Named Inventor	Masakatsu KANEKO et al
				Group Art Unit	1623
				Examiner Name	
Sheet	3	of	6	Attorney Docket Number	01376CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
HO		HO et al, "Treatment of severe lichen planus with cyclosporine", <u>J. Am. Acad. Dermatol.</u> , 1990, Vol. 22, No. 1, pp. 64-68.	
HO		GUM et al, "Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitrogen-activated Protein Kinase...", <u>J. Biol. Chem.</u> , 1996, Vol. 271, No. 18, pp. 10672-10680.	
HO		LITWIN et al, "Novel Cytokine-independent Induction of Endothelial Adhesion Molecules Regulated by Platelet/Endothelial Cell Adhesion Molecule (CD31)", <u>J. Cell Biol.</u> , 1997, Vol. 139, No. 1, pp. 219-228.	
HO		NEWMAN, "Perspective Series: Cell Adhesion in Vascular Biology", <u>J. Clin. Invest.</u> , 1997, Vol. 99, No. 1, pp. 3-8.	
HO		HAKUGAWA et al, "The Inhibitory Effect of Anti-Adhesion Molecule Antibodies on Eosinophil...", <u>J. Dermatol.</u> , 1997; Vol. 24, pp. 73-79.	
HO		DEMERS et al, "Enhanced PCR amplification of VNTR locus D1S80 using peptide nucleic acid (PNA)", <u>Nucl. Acid Res.</u> , 1995, Vol. 23, No. 15, pp. 3050-3055.	
HO		SHEA et al, "Synthesis, Hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates", <u>Nucl. Acid Res.</u> , 1990, Vol. 18, No. 13, pp. 3777-3783.	
HO		OBERHAUSER et al, "Effective incorporation of 2'-O-methyl-oligoribonucleotides into liposomes and enhanced cell association...", <u>Nucl. Acid Res.</u> , 1992, Vol. 20, No. 3, pp. 533-538.	
HO		REGESI et al, "Vascular adhesion molecules in oral lichen planus", <u>Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.</u> , 1996, Vol. 81, No. 6, pp. 682-690.	
		HEGEMANN et al, "BIOCHEMICAL PHARMACOLOGY OF PROTEIN KINASE C AND ITS RELEVANCE FOR DERMATOLOGY", <u>Pharmacol. of the Skin</u>, 1992, Chapter 22, pp. 337-368.	
Examiner Signature	<i>Howard Jones</i>		Date Considered
			7-6-03


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPBP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: **November 7, 2001**

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/925,673
				Filing Date	August 9, 2001
				First Named Inventor	Masakatsu KANEKO et al
				Group Art Unit	1623
				Examiner Name	
Sheet	4	of	6	Attorney Docket Number	01376CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
#0		BERNHARD et al, "Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase)...", <u>Proc. Natl. Acad. Sci. USA</u> , 1994, Vol. 91, pp. 4293-4297.	
#0		DEAN et al, "Inhibition of protein kinase C-α expression in mice after systemic administration...", <u>Prac. Natl. Acad. Sci. USA</u> , 1994, Vol. 91, pp. 11762-11766.	
#0		LETSINGER et al, "Cholesteryl-conjugated oligonucleotides: Synthesis, properties and activity...", <u>Prac. Natl. Acad. Sci. USA</u> , 1989, Vol. 86, pp. 6553-6556.	
#0		RUBIN et al, "Biology of Disease - Insulin-Like Growth Factor-I Receptor", <u>R. Lab. Invest.</u> , 1995, Vol. 73, No. 3, pp. 311-331.	
#0		ERWIN, "The Mother of Mass Extinctions", <u>Sci. Amer.</u> , 1996, 275, pp. 72-78.	
#0		CRAWFORD, "The Mixed Blessing of Inexpensive Oil", <u>Science</u> , 1988, Vol. 242, pp. 1242-1243.	
#0		WAHLESTEDT et al, "Modulation of anxiety and Neuropeptide Y-Y1 Receptors by Antisense Oligodeoxynucleotides", <u>Science</u> , 1993, Vol. 259, pp. 528-531.	
#0		KOSHKIN et al, "LNA (Locked Nucleic Acids): Synthesis of the Adenine, Cytosine, Guanine, 5-Methylcytosine..." <u>Tetrahedron</u> , 1998, 54, pp. 3607-3630.	
#0		KROSCWITZ, Editor, <u>Concise Encyclopedia of Polymer Science and Engineering</u> , 1990, pp. 858-859.	
#0		BERKOW et al, Editors, <u>The Merck Manual of Diagnosis and Therapy</u> , 1987, 15 th Edition, pp. 2263-2277.	
Examiner Signature			Date Considered
			7-603


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: **November 7, 2001**

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/925,673
				Filing Date	August 9, 2001
				First Named Inventor	Masakatsu KANEKO et al
				Group Art Unit	1623
				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	01376CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
Ho		MORASSUTTI et al, "Reduction of <i>mdr1</i> Gene Amplification in Human Multidrug-Resistant LoV1 DX Cell Line...", <u>Antisense & Nucleic Acid Drug Dev.</u> , 1999, 9, pp. 261-270.		
Ho		EBBINGHAUS et al, "Inhibition of Transcription Elongation in the HER-2/neu Coding Sequence...", <u>Biochemistry</u> , 1999, 38, pp. 619-628.		
Ho		CATAPANO et al, "Inhibition of Gene Expression and Cell Proliferation of Triple Helix-Forming Oligonucleotides...", <u>Biochemistry</u> , 2000, 39, pp. 5126-5138.		
Ho		YU et al, "Specific Inhibition of PCR by Non-Extendable Oligonucleotides Using a 5' to 3' Exonuclease-Deficient DNA Polymerase, <u>BioTechniques</u> , 1997, Vol. 23, No. 4, pp. 714-720.		
Ho		RESNICOFF et al, "Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA", <u>Cancer Immunol. Immunother.</u> , 1996, 42, pp. 64-68.		
Ho		RESNICOFF et al, "Rat Glioblastoma Cells Expressing an Antisense RNA to the Insulin-like Growth...", <u>Cancer Research</u> , 1994, 54, pp. 2218-2222.		
Ho		PASS et al, "Inhibition of Hamster Mesothelioma Tumorigenesis by an Antisense Expression Plasmid to the Insulin-like Growth Factor-1 Receptor", <u>Cancer Research</u> , 1996, 56, pp. 4044-4048.		
Ho		HUA et al, "Inhibition of Matrix Metalloproteinase 9 Expression by a Ribozyme Blocks Metastasis in a Rat Sarcoma Model System", <u>Cancer Research</u> , 1996, 56, pp. 5279-5284.		
Ho		SINGH et al, "LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition", <u>Chem. Communication</u> , 1998, 4, pp. 455-456.		
Ho		HURTENBACH et al, "PREDNISOLONE REDUCES EXPERIMENTAL ARTHRITIS AND INFLAMMATORY TISSUE DESTRUCTION IN SCID MICE INFECTED WITH <i>BORRELIA BURGDORFERI</i> ", <u>Int. J. Immunopharmac.</u> , 1996, Vol. 18, No. 5, pp. 281-288.		
Examiner Signature			Date Considered	7-6-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPBP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: **November 7, 2001**

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/925,673
				Filing Date	August 9, 2001
				First Named Inventor	Masakatsu KANEKO et al
				Group Art Unit	1623
				Examiner Name	
Sheet	6	of	6	Attorney Docket Number	01376CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
HO		CROOKE et al, "Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in mice", <u>J. Pharmacol. & Exp. Ther.</u> , 1996, Vol. 277, No. 2, pp. 923-937.	
HO		WAHLESTEDT et al, "Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons..." <u>Nature</u> , 1993, Vol. 363, pp. 260-263.	
HO		PORRECA et al, "A comparison of the potential role of the tetrodotoxin-insensitive sodium channels..." <u>Proc. Natl. Acad. Sci. USA</u> , 1999, Vol. 96, pp. 7640-7644.	
HO		RININSLAND et al, "Suppression of insulin-like growth factor type I receptor by a triple-helix strategy..." <u>Proc. Natl. Acad. Sci. USA</u> , 1997, Vol. 94, pp. 5854-5859.	
HO		GIOVANNANGELI et al, "Triple-helix formation by oligonucleotides containing the three bases thymine, cytosine, and guanine", <u>Proc. Natl. Acad. Sci. USA</u> , 1992, Vol. 89, pp. 8631-8635.	
HO		IYER et al, "A Novel Nucleoside Phosphoramidite Synthon Derived from 1R,2s-Ephedrine", <u>Tetrahedron Asymmetry</u> , 1995, Vol. 6, No. 5, pp. 1051-1054.	
HO		MANOHARAN et al, "LIPIDIC NUCLEIC ACIDS", <u>Tetrahedron Letters</u> , 1995, Vol. 36, No. 21, pp. 3651-3654.	
HO		OBIKA et al, "Stability and structural features of the duplexes containing nucleoside analogues..." <u>Tetrahedron Letters</u> , 1998, Vol. 39, pp. 5401-5404.	
HO		ALBERT et al, "Antisense knockouts: molecular scalpels for the dissection of signal transduction", <u>Trends in Pharmacol. Sci.</u> , 1994, Vol. 15, pp. 250-254.	
Examiner Signature	<i>Armed Elen</i>		Date Considered
			9-6-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPBP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: **November 7, 2001**

Please type a plus sign (+) in this box →

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/925,673
		Filing Date	August 9, 2001
		First Named Inventor	Masakatsu KANEKO et al.
		Group Art Unit	1623
		Examiner Name	
Sheets	1	Attorney Docket Number	01376CIP

U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
		10/054,300		IMANISHI et al.		

FOREIGN PATENT DOCUMENTS

Exam. Inits*	Cite No ¹	Offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶

Examiner Signature

[Handwritten Signature]

Date Considered

7/6/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE MAILED: MARCH 11, 2002

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/925,673
				Filing Date	August 9, 2001
				First Named Inventor	Masakatsu KANEKO et al.
				Group Art Unit	1623
				Examiner Name	Howard Owens, Jr.
Sheet	1	of	1	Attorney Docket Number	01376CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
HO		GIROTRA, Narindar N., et al., "Novel Transformations of Zaragozic Acid A Derivatives with Cesium Fluoride", <u>Tetrahedron Letters</u> , 40(13); (1999), pp. 2485-2488.	
HO		PROCOPIOU, Panayiotis A., et al., "The Squalostatins: Cleavage of the Bicyclic Core Via the Novel 6,8-Dioxabicyclo[3.2.1]Octane Ring System", <u>Journal of the Chemical Society</u> , Perkin Trans. 1: Organic and Bio-Organic Chemistry, (11), (1995), pp. 1341-1347.	
HO		CHAN, Chuen, et al., "The Squalostatins: C-3 Decarboxylation Studies and Rearrangement to the 6,8-Dioxabicyclo[3.2.1]Octane Ring System", <u>Tetrahedron Letters</u> , 34(38), (1993), pp. 6143-6146.	
RECEIVED APR 03 2003 TECH CENTER 1600/2900			
Examiner Signature		<i>Howard Owens</i>	Date Considered
			5/29/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: **MARCH 31, 2003**